CClinicalTrials.gg
Not yet recruitingNCT07392307DED-DMEUpdated Feb 6, 2026

Association Between Dry Eye Disease and Diabetic Macular Edema

An observational study in Dry Eye Disease (DED) , Diabetic Macular Edema, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Sohag University · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2026, 5 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
50
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study evaluates the association between dry eye disease (DED) and diabetic macular edema (DME) in adult patients at the Ophthalmology Department, Faculty of Medicine, Sohag University. Participants will undergo standardized assessments for dry eye and clinical evaluation for macular edema. The goal is to improve understanding of the relationship between these two eye conditions in patients with diabetes.

Read the detailed description

This prospective observational cross-sectional study investigates the relationship between Dry Eye Disease (DED) and Diabetic Macular Edema (DME) in adult diabetic patients at the Ophthalmology Department, Faculty of Medicine, Sohag University.

Participants undergo comprehensive ocular assessments during a single baseline visit, including:

DED evaluation: Ocular Surface Disease Index (OSDI) questionnaire, tear film break-up time (TBUT), Schirmer test, and slit-lamp ocular surface examination.

DME assessment: Clinical fundus examination and Optical Coherence Tomography (OCT) imaging.

The study aims to identify associations between anterior segment (ocular surface) parameters and posterior segment pathology (macular edema), to improve understanding of diabetic ocular complications and inform future screening and management strategies.

The study design is cross-sectional (all assessments at a single visit) and prospective regarding enrollment and data collection at baseline.

02

Conditions studied

  • Dry Eye Disease (DED) , Diabetic Macular Edema

Keywords

  • Dry eye disease
  • Diabetic macular edema
  • Diabetes mellitus
  • Ocular surface
  • Optical coherence tomography (OCT)
  • Ophthalmology
03

In context

Dry Eye Syndromes

1,292 studies on the registry are indexed under Dry Eye Syndromes; 191 are open to participants now.

This study's planned enrollment of 50 is below the median of 90 across 171 observational studies indexed under Dry Eye Syndromes.

Browse Dry Eye Syndromes studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

50 patients with diabetes aged 18-60 years, including 25 patients with diabetic macular edema and 25 patients without macular edema.

Design : This cross-sectional observational study aims to assess ocular and systemic characteristics associated with diabetic macular edema

Inclusion criteria

  • Adults aged 18-60 years.
  • Confirmed diagnosis of diabetes mellitus >8 years.
  • Ability to undergo OCT examination.
  • Ability to perform standardized dry eye diagnostic tests.
  • Signed informed consent after explanation of study purpose.

Exclusion criteria

Exclusion Criteria:

  • History of ocular surgery.
  • History of Argon laser photocoagulation.
  • Advanced proliferative diabetic retinopathy (PDR): tractional retinal detachment, vitreous hemorrhage, optic neuropathy.
  • Previous significant ocular trauma.
  • Presence of other ocular surface diseases, or history of systemic or ocular surgeries affecting the eye.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1: Participants with Diabetic Macular Edema (DME)

    Participants diagnosed with DME. Dry Eye Disease (DED) will be assessed using imaging and clinical evaluation (OSDI questionnaire, TBUT, Schirmer test, ocular surface examination).

    Diagnostic Test: Dry Eye Disease Assessment

  • Group 2: Participants without DME

    Participants without DME. Dry Eye Disease (DED) will be assessed using imaging and clinical evaluation (OSDI questionnaire, TBUT, Schirmer test, ocular surface examination).

    Diagnostic Test: Dry Eye Disease Assessment

Interventions

  • Diagnostic testDry Eye Disease Assessment

    Assessment of dry eye symptoms, tear film function, and ocular surface examination using standardized questionnaires and clinical tests (OSDI, TBUT, Schirmer test).

06

What researchers measure

Primary outcomes

  1. Dry Eye Disease (DED) Symptom Severity

    DED symptoms will be assessed using the Ocular Surface Disease Index (OSDI) questionnaire to quantify ocular discomfort, visual disturbance, and functional limitations. Units of Measure: OSDI score (0-100)

    Time frame: Baseline (single visit)

  2. Tear Film Function

    Tear film function will be evaluated using Tear Break-Up Time (TBUT) to measure tear film stability and the Schirmer test to assess tear production. Three consecutive measurements are averaged for TBUT; Schirmer test is performed over 5 minutes. Units of Measure: TBUT in seconds; Schirmer test in millimeters (mm)

    Time frame: Baseline (single visit)

  3. Diabetic Macular Edema (DME) Severity

    Diabetic Macular Edema (DME) Severity Description: DME severity will be assessed by clinical fundus examination and Optical Coherence Tomography (OCT) imaging to determine the presence and severity of macular edema. Central macular thickness and retinal fluid are measured. Units of Measure: Macular thickness in micrometers (µm); clinical grading of edema.

    Time frame: Baseline (single visit)

07

Study locations

1 site
08

References and documents

Publications

  • Manaviat MR, Rashidi M, Afkhami-Ardekani M, Shoja MR. Prevalence of dry eye syndrome and diabetic retinopathy in type 2 diabetic patients. BMC Ophthalmol. 2008 Jun 2;8:10. doi: 10.1186/1471-2415-8-10. PubMed 18513455 ↗
  • Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017 Jul;15(3):276-283. doi: 10.1016/j.jtos.2017.05.008. Epub 2017 Jul 20. PubMed 28736335 ↗

Individual participant data

Plan to share: Undecided — Plans to share Individual Participant Data (IPD) are currently undecided. Any future sharing will follow ethical approvals, institutional policies, and measures to protect participant confidentiality.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07392307
Lead sponsor
Sohag University
Responsible party
Esraa Aly (Resident doctor, Ophthalmology department, sohag teaching hospital, Sohag University) — Principal investigator
First posted
Feb 6, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Apr 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Feb 6, 2026

Study contacts

Esraa A Ahmed, M.B.B.Ch
Contact
esraaaly@med.sohag.edu.eg
+201022649668
Mohamed I Hafez, MD, PhD
Contact
+201068559840
Islam A Ahmed, MD,PhD
study director · Sohag University, Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion